Table 29 |
|||||
|
Further sensitivity analyses for smoking-adjusted data. Effect of preferring estimates for current smokeless tobacco use to those for ever or unspecified smokeless tobacco use |
|||||
|
Heterogeneity |
|||||
|
|
|||||
|
Cancer |
Analysisa |
N (nc)b |
Random-effects RR/OR (95% CI) |
χ2 |
P |
|
|
|||||
|
Oropharyngeal |
Table 4 |
19 |
1.36 (1.04–1.77) |
69.5 |
< 0.001 |
|
Sensitivity |
(5) |
1.42 (1.10–1.84) |
51.1 |
< 0.001 |
|
|
Oesophageal |
Table 6 |
7 |
1.13 (0.95–1.36) |
4.4 |
0.623 |
|
Sensitivity |
(2) |
1.11 (0.92–1.34) |
4.1 |
0.665 |
|
|
Stomach |
Table 8 |
8 |
1.03 (0.88–1.20) |
10.3 |
0.173 |
|
Sensitivity |
(2) |
1.01 (0.86–1.19) |
10.4 |
0.165 |
|
|
Pancreatic |
Table 10 |
7 |
1.07 (0.71–1.60) |
21.5 |
0.001 |
|
Sensitivity |
(2) |
1.22 (0.75–2.01) |
23.1 |
< 0.001 |
|
|
Overall digestive |
Table 12 |
5 |
0.86 (0.59–1.25) |
17.3 |
0.002 |
|
Sensitivity |
(1) |
0.85 (0.57–1.27) |
17.3 |
0.002 |
|
|
Larynx |
Table 14 |
2 |
1.34 (0.61–2.95) |
4.0 |
0.044 |
|
Sensitivity |
(1) |
1.45 (0.73–2.88) |
2.5 |
0.116 |
|
|
Lung |
Table 16 |
6 |
0.99 (0.71–1.37) |
28.7 |
< 0.001 |
|
Sensitivity |
(3) |
1.11 (0.73–1.69) |
20.6 |
< 0.001 |
|
|
Prostate |
Table 18 |
4 |
1.29 (1.07–1.55) |
1.2 |
0.764 |
|
Sensitivity |
(0) |
||||
|
Bladder |
Table 20 |
10 |
0.95 (0.71–1.29) |
22.3 |
0.008 |
|
Sensitivity |
(1) |
0.94 (0.68–1.29) |
23.7 |
0.005 |
|
|
Kidney |
Table 22 |
5 |
1.09 (0.69–1.71) |
6.9 |
0.142 |
|
Sensitivity |
(1) |
1.07 (0.60–1.91) |
9.6 |
0.048 |
|
|
Non-Hodgkin's lymphoma |
Table 24 |
3 |
1.35 (0.62–2.94) |
9.5 |
0.009 |
|
Sensitivity |
(0) |
||||
|
Overall |
Table 27 |
7 |
0.98 (0.84–1.15) |
27.1 |
< 0.001 |
|
Sensitivity |
(1) |
0.99 (0.83–1.17) |
27.9 |
< 0.001 |
|
|
|
|||||
|
a For each cancer the first line repeats the original results preferring ever or unspecified ST use shown in the Table indicated, while the second line presents the results of the sensitivity analysis preferring current ST use. b N is the number of estimates included in the original and sensitivity analyses; nc is the number of changed estimates. For each cancer, the identification numbers for the estimates (shown in the Table indicated) included in the sensitivity analysis are shown below, with those not used in the original analysis in italic. Oropharyngeal (Table 3): 2, 3, 4, 8, 11, 13, 18, 26, 35, 43, 48, 51, 55, 56, 58, 61, 70, 74, 75 Oesophageal (Table 5): 3, 6, 10, 11, 19, 20, 23 Stomach (Table 7): 1, 4, 7, 10, 14, 17, 19, 21 Pancreatic (Table 9): 1, 3, 8, 11, 16, 18, 23 Overall digestive (Table 11): 4, 5, 6, 7, 19 Larynx (Table 13): 3, 14 Lung (Table 15): 2, 3, 4, 9, 14, 20 Prostate (Table 17): 1, 3, 5, 7 Bladder (Table 19): 1, 4, 8, 9, 12, 17, 21, 22, 27, 31 Kidney (Table 21): 1, 5, 13, 17, 19 Non-Hodgkin's lymphoma (Table 23): 5, 13, 19 Overall cancer (Table 26): 1, 2, 3, 4, 9, 10, 12 CI = confidence interval; OR = odds ratio; RR = relative risk. |
|||||
|
Lee and Hamling BMC Medicine 2009 7:36 doi:10.1186/1741-7015-7-36 |
|||||
